Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
DarioHealth ( (DRIO) ) has shared an update.
On May 20, 2025, DarioHealth Corp. amended and restated the certificates of designation for its Series C, C-1, and C-2 Preferred Stocks by extending the mandatory conversion period from 15 to 24 months. This change also includes issuing a 15% dividend of common stock for each full quarter anniversary of holding the preferred stocks, impacting the company’s financial operations but not resulting in the issuance of new securities.
The most recent analyst rating on (DRIO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on DarioHealth stock, see the DRIO Stock Forecast page.
Spark’s Take on DRIO Stock
According to Spark, TipRanks’ AI Analyst, DRIO is a Neutral.
DarioHealth’s overall score reflects financial challenges, such as negative cash flow and high leverage, which overshadow revenue growth and client acquisition. Technical indicators are mixed, and valuation is hindered by negative earnings. The recent credit agreement and optimistic guidance provide some positive outlook, but significant improvements in financial health are necessary for a higher score.
To see Spark’s full report on DRIO stock, click here.
More about DarioHealth
Average Trading Volume: 243,858
Technical Sentiment Signal: Sell
Current Market Cap: $29.01M
For an in-depth examination of DRIO stock, go to TipRanks’ Stock Analysis page.